Patients expressing ULBP2 and ULBP3 had a lower rate of FEV1 decline over 48 months (-124 ± 30 mL/year) than patients without serum sNKG2DLs (-32.7 ± 10 mL/year) (p < 0.05) [71], which meant the presence of sNKG2DLs might be related to the pulmonary cystic destruction in LAM patients. Here, ULBP2 is linked to lymphangioleiomyomatosis.